Abuse potential of dronabinol (Marinol).
Dronabinol is an oral form of delta-9-tetrahydrocannabinol indicated for treatment of anorexia associated with weight loss in individuals with AIDS, and nausea and vomiting associated with cancer chemotherapy. The authors reviewed the literature and conducted surveys and interviews among addiction medicine specialists, oncologists, researchers in cancer and HIV treatment, and law enforcement personnel to determine the abuse liability of dronabinol. There is no evidence of abuse or diversion of dronabinol. Available prescription tracking data indicates that use remains within the therapeutic dosage range over time. Healthcare professionals have detected no indication of "scrip-chasing" or "doctor-shopping" among the patients for whom they have prescribed dronabinol. Cannabis-dependent populations, such as those treated in our Clinic and seen by the addiction medicine specialists we interviewed, have demonstrated no interest in abuse of dronabinol. There is no street market for dronabinol, and no evidence of any diversion of dronabinol for sale as a street drug. Furthermore, dronabinol does not provide effects that are considered desirable in a drug of abuse. The onset of action is slow and gradual, it is at most only weakly reinforcing, and the overwhelming majority of reports of users indicate that its effects are dysphoric and unappealing. This profile of effects gives dronabinol a very low abuse potential.
Haight Ashbury Free Clinics, Inc., San Francisco, California 94117, USA.
S R
SR
Calhoun
G P
GP
Galloway
D E
DE
Smith
D000932:Antiemetics / Q000009:adverse effects*; D019167:Appetite Stimulants / Q000009:adverse effects*; D003625:Data Collection; D013759:Dronabinol / Q000009:adverse effects*; D006801:Humans; D019966:Substance-Related Disorders
D000932:Antiemetics; D019167:Appetite Stimulants; D013759:Dronabinol